Literature DB >> 9733822

Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections.

K S Cole1, M Murphey-Corb, O Narayan, S V Joag, G M Shaw, R C Montelaro.   

Abstract

Characterization of virus-specific immune responses to human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) is important to understanding the early virus-host interactions that may determine the course of virus infection and disease. Using a comprehensive panel of serological assays, we have previously demonstrated a complex and lengthy maturation of virus-specific antibody responses elicited by attenuated strains of SIV that was closely associated with the development of protective immunity. In the present study, we expand these analyses to address several questions regarding the nature of the virus-specific antibody responses to pathogenic SIV, SIV/HIV-1 (SHIV), and HIV-1 infections. The results demonstrate for the first time a common theme of antibody maturation to SIV, SHIV, and HIV-1 infections that is characterized by ongoing changes in antibody titer, conformational dependence, and antibody avidity during the first 6 to 10 months following virus infection. We demonstrate that this gradual evolution of virus-specific antibody responses is independent of the levels of virus replication and the pathogenicity of the infection viral strain. While the serological assays used in these studies were useful in discriminating between protective and nonprotective antibody responses during evaluation of vaccine efficacy with attenuated SIV, these same assays do not distinguish the clinical outcome of infection in pathogenic SIV, SHIV, or HIV-1 infections. These results likely reflect differences in the immune mechanisms involved in mediating protection from virus challenge compared to those that control an established viral infection, and they suggest that additional characteristics of both humoral and cellular responses evolve during this early immune maturation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9733822      PMCID: PMC110105     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

Review 1.  Antibody affinity and protection in virus infections.

Authors:  A A Salmi
Journal:  Curr Opin Immunol       Date:  1991-08       Impact factor: 7.486

2.  An investigation of the high-avidity antibody response to glycoprotein 120 of human immunodeficiency virus type 1.

Authors:  J M Binley; H Arshad; T R Fouts; J P Moore
Journal:  AIDS Res Hum Retroviruses       Date:  1997-08-10       Impact factor: 2.205

3.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR.

Authors:  M Piatak; M S Saag; L C Yang; S J Clark; J C Kappes; K C Luk; B H Hahn; G M Shaw; J D Lifson
Journal:  Science       Date:  1993-03-19       Impact factor: 47.728

4.  High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection.

Authors:  S J Clark; M S Saag; W D Decker; S Campbell-Hill; J L Roberson; P J Veldkamp; J C Kappes; B H Hahn; G M Shaw
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

5.  Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain.

Authors:  Y Devash; T A Calvelli; D G Wood; K J Reagan; A Rubinstein
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

6.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

7.  Antibody avidity measurement and immune complex dissociation for serological diagnosis of vertically acquired HIV-1 infection.

Authors:  F Simon; C Rahimy; A Krivine; M Levine; J M Pepin; D Lapierre; E Denamur; L Vernoux; A De Crepy; P Blot
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-02

8.  A longitudinal study of the IgG antibody response to HIV-1 p17 gag protein in HIV-1+ patients with haemophilia: titre and avidity.

Authors:  D Chargelegue; C M O'Toole; B T Colvin
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

9.  Monitoring of antibodies against human immunodeficiency virus type 1 p25 core protein as prognostic marker.

Authors:  E Fenouillet; N Blanes; A Coutellier; J Demarquest; W Rozenbaum; J C Gluckman
Journal:  J Infect Dis       Date:  1992-09       Impact factor: 5.226

10.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.

Authors:  J P Moore; D D Ho
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  29 in total

1.  Immune responses and viral replication in long-term inapparent carrier ponies inoculated with equine infectious anemia virus.

Authors:  S A Hammond; F Li; B M McKeon; S J Cook; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance.

Authors:  J D Steckbeck; H J Grieser; T Sturgeon; R Taber; A Chow; J Bruno; M Murphy-Corb; R C Montelaro; K S Cole
Journal:  J Med Primatol       Date:  2006-08       Impact factor: 0.667

3.  Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251.

Authors:  Koen K A Van Rompay; Jennifer L Greenier; Kelly Stefano Cole; Patricia Earl; Bernard Moss; Jonathan D Steckbeck; Bapi Pahar; Tracy Rourke; Ronald C Montelaro; Don R Canfield; Ross P Tarara; Christopher Miller; Michael B McChesney; Marta L Marthas
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Immune suppression of challenged vaccinates as a rigorous assessment of sterile protection by lentiviral vaccines.

Authors:  Jodi K Craigo; Shannon Durkin; Timothy J Sturgeon; Tara Tagmyer; Sheila J Cook; Charles J Issel; Ronald C Montelaro
Journal:  Vaccine       Date:  2006-09-22       Impact factor: 3.641

5.  Impact of Poxvirus Vector Priming, Protein Coadministration, and Vaccine Intervals on HIV gp120 Vaccine-Elicited Antibody Magnitude and Function in Infant Macaques.

Authors:  Bonnie Phillips; Genevieve G Fouda; Josh Eudailey; Justin Pollara; Alan D Curtis; Erika Kunz; Maria Dennis; Xiaoying Shen; Camden Bay; Michael Hudgens; David Pickup; S Munir Alam; Amir Ardeshir; Pamela A Kozlowski; Koen K A Van Rompay; Guido Ferrari; M Anthony Moody; Sallie Permar; Kristina De Paris
Journal:  Clin Vaccine Immunol       Date:  2017-10-05

6.  Monoclonal antibodies to conformational epitopes of the surface glycoprotein of caprine arthritis-encephalitis virus: potential application to competitive-inhibition enzyme-linked immunosorbent assay for detecting antibodies in goat sera.

Authors:  F Ozyörük; W P Cheevers; G A Hullinger; T C McGuire; M Hutton; D P Knowles
Journal:  Clin Diagn Lab Immunol       Date:  2001-01

Review 7.  Viral sequence diversity: challenges for AIDS vaccine designs.

Authors:  Sean P McBurney; Ted M Ross
Journal:  Expert Rev Vaccines       Date:  2008-11       Impact factor: 5.217

8.  Removal of N-linked glycosylation sites in the V1 region of simian immunodeficiency virus gp120 results in redirection of B-cell responses to V3.

Authors:  Kelly Stefano Cole; Jonathan D Steckbeck; Jennifer L Rowles; Ronald C Desrosiers; Ronald C Montelaro
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

9.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

10.  An EIAV field isolate reveals much higher levels of subtype variability than currently reported for the equine lentivirus family.

Authors:  Jodi K Craigo; Shannon Barnes; Baoshan Zhang; Sheila J Cook; Laryssa Howe; Charles J Issel; Ronald C Montelaro
Journal:  Retrovirology       Date:  2009-10-20       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.